Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.

Me CEO Anne Wojcicki continues to maintain a strong outlook despite recent high-profile stumbles. “We are a long-term company ...

Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million ...

Here are five top Goldman Sachs dividend-paying stock picks that investors can buy now and hold for the next decade or longer ...

Engineering-procurement-construction (EPC) companies deliver deliver under a single contract, and the biggest include Danaher ...

A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...

Its cheap valuation, strong growth prospects, and massive dividend make it ripe for outsize investment returns.

The XEC strain, a hybrid of Omicron subvariants KS.1.1 and KP.3.3, was first detected in Canada in mid-August and the number ...

Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...

Platelets are cells that help your blood clot, and it was so unusual to see blood clots combined with low platelet levels, ...

Zachary Levi, known for his role as the titular character in Shazam! Fury of the Gods, is facing financial difficulties after ...

Michela Tindera But despite losing Read and D’Amelio’s support, Starboard is still pushing ahead with its campaign. Yesterday, October 22nd, at an activist investor conference in New York, Starboard ...